Research programme: axon regeneration therapies - Alseres Pharmaceuticals

Drug Profile

Research programme: axon regeneration therapies - Alseres Pharmaceuticals

Alternative Names: ALSE-100; CBP-15 calcium-binding protein; MDP14; OCM protein; Oncomodulin

Latest Information Update: 19 Jan 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Childrens Hospital Boston
  • Developer Alseres Pharmaceuticals
  • Class Calcium binding proteins
  • Mechanism of Action Neuron stimulants; Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Brain injuries; Cardiomyopathies; Eye disorders; Spinal cord injuries

Most Recent Events

  • 19 Nov 2008 Pharmacodynamics data from a preclinical trial in Eye disorders presented at the the 38th Annual Meeting for the Society of Neuroscience (SfN-2008)
  • 26 May 2008 The Regenerative Therapeutics programme is available for licensing (http://www.alseres.com)
  • 08 Jun 2007 Boston Life Sciences is now called Alseres Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top